DOCSLIB.ORG

Supplementary Table S4

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplementary Table S4 Supplementary Table 4 - Patient P10 Heat maps of mutations and gene expression for patients with three or more tumor sample analyzed. P10 SNV Allele frequency Log2(FPKM+1) GeneSymbol S1 S5 S8 S1 S5 S8 S1 S5 S8 Ref KDM6A* 1 1 1 0.82 0.87 0.64 2.36 2.28 2.22 3.01 UBAP2L 1 1 1 0.63 0.58 0.47 4.72 5.10 5.33 4.78 SLC12A5 1 1 1 0.60 0.32 0.29 0.05 0.01 0.00 0.02 KDM6A FMO1 1 1 1 0.59 0.56 0.41 0.23 0.04 0.40 0.14 MCC 1 1 1 0.58 0.46 0.49 4.33 5.29 4.99 4.54 3.50 MCAM 1 1 1 0.57 0.38 0.38 2.73 2.60 3.95 3.11 CCDC60 1 1 1 0.52 0.47 0.36 0.06 0.01 0.00 1.58 3.00 RALYL 1 1 1 0.52 0.25 0.24 0.03 0.03 0.00 0.15 2.50 AGXT 1 1 1 0.50 0.40 0.29 0.01 0.00 0.00 0.04 FAM209B 1 1 1 0.46 0.33 0.35 0.01 0.02 0.02 0.09 2.00 MYO7B 1 1 1 0.45 0.52 0.34 0.01 0.00 0.01 0.13 PPARG 1 1 1 0.45 0.48 0.34 5.55 5.93 5.70 5.92 1.50 MUC4 1 1 1 0.44 0.42 0.29 0.17 0.12 0.05 0.67 Log2(FPKM+1) HRAS** 1 1 1 0.44 0.39 0.20 4.32 4.75 4.55 3.28 1.00 MIA3 1 1 1 0.39 0.38 0.19 5.30 5.35 5.15 4.70 0.50 CLTC# 1 1 1 0.39 0.39 0.37 5.57 5.93 5.81 6.05 CEP152 1 1 1 0.38 0.43 0.17 3.28 2.78 3.25 2.14 0.00 DDC 1 1 1 0.38 0.34 0.29 0.01 0.01 0.00 0.12 S1 S5 S8 Ref HERC2 1 1 1 0.38 0.36 0.25 3.60 3.77 3.09 3.14 SEMA3D 1 1 1 0.37 0.51 0.26 0.38 0.60 0.53 2.83 ZNF320 1 1 1 0.34 0.41 0.22 4.14 4.25 4.08 4.07 HRAS ERBB3# 1 1 1 0.34 0.39 0.26 5.52 5.85 5.60 4.69 KSR2 1 1 1 0.33 0.39 0.27 0.75 1.17 0.65 0.97 5.00 TRERF1 1 1 1 0.32 0.42 0.27 2.10 2.45 2.25 2.63 4.50 COG4 1 1 1 0.31 0.36 0.27 3.78 4.06 4.12 3.58 4.00 LPAR5 1 1 1 0.31 0.43 0.24 0.92 1.03 0.47 1.17 3.50 PRTN3 1 1 1 0.30 0.05 0.02 0.01 0.00 0.00 0.00 BDP1 1 1 1 0.29 0.42 0.29 4.18 4.34 3.98 3.62 3.00 RYR2 1 1 1 0.29 0.26 0.19 0.80 0.24 0.90 1.08 2.50 SAFB 1 1 1 0.29 0.47 0.35 4.44 4.46 4.90 3.96 2.00 SEMA6D 1 1 1 0.26 0.40 0.29 1.17 0.85 1.51 2.25 Log2(FPKM+1) 1.50 CROCC 1 1 1 0.25 0.31 0.16 2.86 2.73 2.76 1.83 HECW1 1 1 1 0.21 0.37 0.34 0.07 0.08 0.04 0.63 1.00 ZBTB45 1 1 1 0.21 0.41 0.21 0.66 0.60 0.78 0.92 0.50 PLXNB2 1 1 1 0.17 0.13 0.02 4.99 5.31 5.39 4.57 0.00 MROH7 1 1 1 0.12 0.04 0.01 S1 S5 S8 Ref CCDC40 1 1 1 0.12 0.03 0.05 0.30 0.25 0.68 1.04 NIPAL4 1 1 1 0.09 0.02 0.02 3.23 3.79 3.37 2.75 CYP2A7 1 1 1 0.07 0.09 0.01 0.00 0.01 0.00 0.02 OR4N4 1 1 1 0.06 0.08 0.01 0.00 0.00 0.00 0.00 POU5F1B 1 1 1 0.05 0.05 0.03 0.19 0.26 0.28 0.19 ZNF585A 1 1 1 0.02 0.05 0.05 1.66 1.65 1.49 1.96 AGAP6 1 1 1 0.01 0.04 0.01 2.12 2.23 1.74 1.67 LYPLA2 1 1 0.45 0.32 1.54 1.73 1.80 2.01 COBL 1 1 0.44 0.24 0.03 0.02 0.06 0.76 NELFCD 1 1 0.44 0.26 ATP2B2 1 1 0.42 0.28 0.01 0.01 0.02 0.18 SLC18A1 1 1 0.42 0.31 0.02 0.01 0.00 0.07 HAND2 1 1 0.42 0.23 0.20 0.14 0.46 2.04 ADPRM 1 1 0.40 0.35 0.98 1.15 1.48 1.62 SQLE 1 1 0.35 0.19 2.81 2.81 2.74 2.93 SDF4 1 1 0.33 0.36 4.70 5.27 5.29 4.97 ZNF891 1 1 0.33 0.29 1.48 1.16 1.10 1.66 SSSCA1 1 1 0.31 0.30 1.85 2.44 2.40 2.31 KLHL40 1 1 0.27 0.29 CYP2D6 1 1 0.20 0.06 0.16 0.17 0.27 0.12 SLU7 1 1 0.16 0.21 4.54 4.59 4.82 4.42 TNRC18 1 1 0.12 0.04 4.29 4.58 4.14 3.82 GREB1 1 1 0.12 0.02 0.08 0.18 0.05 0.70 KNDC1 1 1 0.12 0.03 0.03 0.00 0.00 0.18 IL12RB1 1 1 0.09 0.01 0.03 0.07 0.13 0.61 PPEF2 1 1 0.06 0.02 5.55 0.19 1.72 1.84 MUC5B 1 1 0.05 0.01 0.07 0.03 0.00 0.01 KRI1 1 1 0.05 0.12 2.74 2.42 3.48 2.70 KIR3DL2 1 1 0.04 0.02 0.00 0.01 0.00 0.03 P10 SNV Allele frequency Log2(FPKM+1) GeneSymbol S1 S5 S8 S1 S5 S8 S1 S5 S8 Ref MSN 1 1 0.04 0.10 2.81 2.35 3.58 4.31 DMBT1 1 1 0.04 0.01 0.02 0.04 0.20 0.31 CHEK2# 1 1 0.03 0.00 2.23 2.61 1.79 2.39 NOP14 1 1 0.14 0.03 3.96 4.51 4.31 3.65 ELL2 1 0.28 3.74 4.34 4.56 2.97 C21orf58 1 1 0.17 0.14 1.09 1.53 1.16 0.32 TBC1D9B 1 1 0.07 0.09 3.66 4.17 3.86 3.56 OR4N4 1 1 0.07 0.04 0.00 0.00 0.00 0.00 INADL 1 1 0.06 0.06 5.43 6.24 5.22 5.01 CTBP2 1 1 0.06 0.09 3.91 3.58 3.79 2.83 PLIN4 1 1 0.05 0.06 1.89 2.09 1.73 1.42 IL12RB1 1 1 0.05 0.12 0.03 0.07 0.13 0.61 FBN3 1 1 0.05 0.06 0.00 0.01 0.00 0.01 ACSM5 1 1 0.05 0.05 0.12 0.03 0.30 0.41 PER3 1 1 0.04 0.06 1.84 1.83 2.05 2.64 OR8G2 1 1 0.04 0.06 ADAM32 1 0.33 0.50 0.45 0.87 1.39 CHD2 1 0.20 6.30 6.42 6.26 6.39 TCF3 1 0.18 3.06 3.19 2.94 3.06 ZNF99 1 0.17 0.12 0.04 0.11 0.08 PTCRA 1 0.17 0.01 0.00 0.00 0.03 ATP6V1B1 1 0.17 0.12 0.06 0.25 0.09 BARX2 1 0.16 0.17 0.47 0.52 0.09 MGAT5B 1 0.16 0.01 0.00 0.00 0.08 TMPRSS9 1 0.16 0.01 0.00 0.01 0.01 UMODL1 1 0.14 0.01 0.03 0.01 0.02 GABRA4 1 0.13 0.01 0.00 0.02 0.02 FAM179A 1 0.13 0.01 0.00 0.08 0.19 KLHDC4 1 0.10 2.51 2.48 2.43 2.43 SULT1A2 1 0.10 2.10 2.33 1.63 0.96 CXorf64 1 0.10 0.00 0.00 0.00 0.00 SLC38A10 1 0.10 2.81 3.32 3.31 3.01 SLC7A4 1 0.09 0.82 0.97 0.44 0.38 MYO7B 1 0.09 0.01 0.00 0.01 0.13 CYP2D6 1 0.09 0.16 0.17 0.27 0.12 RRP7A 1 0.09 3.46 3.33 3.37 3.33 FBN3 1 0.08 0.00 0.01 0.00 0.01 SPDYE5 1 0.08 DOCK8 1 0.07 4.01 4.26 3.43 3.41 PTPRH 1 0.06 1.02 1.21 1.25 0.51 SLC4A1 1 0.04 0.05 0.00 0.00 0.06 MUC5B 1 0.14 0.07 0.03 0.00 0.01 OPN1LW 1 0.11 0.00 0.00 0.12 0.01 * Tumor suppressor genes ** Oncogenes # Genes fron the IntOGen database Supplementary Table 4 - Patient P11 Heat maps of mutations and gene expression for patients with three or more tumor sample analyzed.
Load more

Recommended publications
  • “A Very Stinking Herbe” Is Cilantro Love/Hate a Genetic Trait? So Fresh Or So Clean? Methods Results and Discussion Referenc
    A Genetic Variant Near Olfactory Receptor Genes Associates With Cilantro Preference S. Wu, J.Y. Tung, A.B. Chowdry, A.K. Kiefer, J.L. Mountain, N. Eriksson 23andMe, Inc., Mountain View, CA “A very stinking herbe”! Many people love the taste of fresh cilantro (Coriandrum sativum, also called coriander), while Oh, coriander.! others despise it with every fiber of their being. The debate has raged for centuries. Pliny extolled If "pure evil# had a taste?! its “refreshing” properties, a medieval herbalist claimed that the leaves had a “venomous quality,” It would taste like you.! by SilverSpoon at and, more recently, beloved culinary icon Julia Child opined that cilantro had “kind of a dead taste” IHateCilantro.com! and that she would “pick it out if [she] saw it and throw it on the floor.”! So fresh or so clean?! Is cilantro love/hate a genetic trait?! Cilantro"s dual nature may lie in its key aroma components, which consist of It is not known why cilantro is so differentially perceived. Cilantro various aldehydes. The unsaturated aldehydes (mostly decanal and preference varies with ancestry and may be influenced by dodecanal) are described as fruity, green, and pungent; the (E)-2-alkenals exposure. Genetic factors are also thought to play a role but to as soapy, fatty, pungent, and “like cilantro.” Of the many descriptors that date no studies have found genetic variants influencing cilantro “haters” use, soapy is the most common.! taste preference. ! Methods! Results and discussion! We conducted the first-ever genome-wide association study of cilantro preference. Participants were drawn from the more than 180,000 genotyped customers of 23andMe, Inc., a consumer genetics company.! Phenotype data collection! Participants reported their age and answered Figure 1.
    [Show full text]
  • Genetic Variation Across the Human Olfactory Receptor Repertoire Alters Odor Perception
    bioRxiv preprint doi: https://doi.org/10.1101/212431; this version posted November 1, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Genetic variation across the human olfactory receptor repertoire alters odor perception Casey Trimmer1,*, Andreas Keller2, Nicolle R. Murphy1, Lindsey L. Snyder1, Jason R. Willer3, Maira Nagai4,5, Nicholas Katsanis3, Leslie B. Vosshall2,6,7, Hiroaki Matsunami4,8, and Joel D. Mainland1,9 1Monell Chemical Senses Center, Philadelphia, Pennsylvania, USA 2Laboratory of Neurogenetics and Behavior, The Rockefeller University, New York, New York, USA 3Center for Human Disease Modeling, Duke University Medical Center, Durham, North Carolina, USA 4Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA 5Department of Biochemistry, University of Sao Paulo, Sao Paulo, Brazil 6Howard Hughes Medical Institute, New York, New York, USA 7Kavli Neural Systems Institute, New York, New York, USA 8Department of Neurobiology and Duke Institute for Brain Sciences, Duke University Medical Center, Durham, North Carolina, USA 9Department of Neuroscience, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA *[email protected] ABSTRACT The human olfactory receptor repertoire is characterized by an abundance of genetic variation that affects receptor response, but the perceptual effects of this variation are unclear. To address this issue, we sequenced the OR repertoire in 332 individuals and examined the relationship between genetic variation and 276 olfactory phenotypes, including the perceived intensity and pleasantness of 68 odorants at two concentrations, detection thresholds of three odorants, and general olfactory acuity.
    [Show full text]
  • Bahl Et Al Revisedmanuscript.Pdf
    This is an electronic reprint of the original article. This reprint may differ from the original in pagination and typographic detail. Author(s): Bahl, Aileen; Pöllänen, Eija; Ismail, Khadeeja; Sipilä, Sarianna; Mikkola, Tuija; Berglund, Eva; Lindqvist, Carl Mårten; Syvänen, Ann-Christine; Rantanen, Taina; Kaprio, Jaakko; Kovanen, Vuokko; Ollikainen, Miina Title: Hormone Replacement Therapy Associated White Blood Cell DNA Methylation and Gene Expression are Associated With Within-Pair Differences of Body Adiposity and Bone Mass Year: 2015 Version: Please cite the original version: Bahl, A., Pöllänen, E., Ismail, K., Sipilä, S., Mikkola, T., Berglund, E., . Ollikainen, M. (2015). Hormone Replacement Therapy Associated White Blood Cell DNA Methylation and Gene Expression are Associated With Within-Pair Differences of Body Adiposity and Bone Mass. Twin Research and Human Genetics, 18 (6), 647-661. doi:10.1017/thg.2015.82 All material supplied via JYX is protected by copyright and other intellectual property rights, and duplication or sale of all or part of any of the repository collections is not permitted, except that material may be duplicated by you for your research use or educational purposes in electronic or print form. You must obtain permission for any other use. Electronic or print copies may not be offered, whether for sale or otherwise to anyone who is not an authorised user. Hormone replacement therapy associated white blood cell DNA methylation and gene expression are associated with within-pair differences of body adiposity
    [Show full text]
  • Sequencing of 50 Human Exomes Reveals Adaptation to High Altitude
    REPORTS Digestive and Kidney Diseases) and The University of Omnibus, with accession code GSE21661. These data, as Figs. S1 to S6 Luxembourg–Institute for Systems Biology Program to well as phenotype data, are also available on our Tables S1 to S12 C.D.H. T.S.S. was supported by NIH Genetics Training laboratory Web site, http://jorde-lab.genetics.utah. References Grant T32. All studies have been performed with edu. Please contact R.L.G. for access to DNA samples. informed consent approved by the Institutional Board of 10 March 2010; accepted 6 May 2010 Qinghai Medical College of Qinghai University in Supporting Online Material Published online 13 May 2010; Xining, Qinghai Province, People’s Republic of China. All www.sciencemag.org/cgi/content/full/science.1189406/DC1 10.1126/science.1189406 SNP genoptypes are deposited in Gene Expression Materials and Methods Include this information when citing this paper. also estimated single-nucleotide polymorphism Sequencing of 50 Human Exomes (SNP) probabilities and population allele frequen- cies for each site. A total of 151,825 SNPs were Reveals Adaptation to High Altitude inferred to have >50% probability of being var- iable within the Tibetan sample, and 101,668 had Xin Yi,1,2* Yu Liang,1,2* Emilia Huerta-Sanchez,3* Xin Jin,1,4* Zha Xi Ping Cuo,2,5* John E. Pool,3,6* >99% SNP probability (table S2). Sanger se- Xun Xu,1 Hui Jiang,1 Nicolas Vinckenbosch,3 Thorfinn Sand Korneliussen,7 Hancheng Zheng,1,4 quencing validated 53 of 56 SNPs that had at least Tao Liu,1 Weiming He,1,8 Kui Li,2,5 Ruibang Luo,1,4 Xifang Nie,1 Honglong Wu,1,9 Meiru Zhao,1 95% SNP probability and minor allele frequencies Hongzhi Cao,1,9 Jing Zou,1 Ying Shan,1,4 Shuzheng Li,1 Qi Yang,1 Asan,1,2 Peixiang Ni,1 Geng Tian,1,2 between 3% and 50%.
    [Show full text]
  • Supporting Information Supplementary Methods Patients for Whole Genome Sequencing and Validation Cohort. Heparinized Bone Marrow
    Supporting Information Supplementary Methods Patients for whole genome sequencing and validation cohort. Heparinized bone marrow samples were obtained from 8 RAEB patients with informed consent for WGS according to the ethics review board of Shanghai Institute of Hematology. Briefly, these 8 patients were 4 RAEB-1, 4 RAEB-2, 5 males, 3 females, 1 with complex karyotype, 1 with +8, 5 with normal karyotype, and classified as intermediate to very high risk level. 6 patients died 4-23 months after diagnosis of infection, hemorrhage, cerebral infarction or evolution to AML (complete information see Table S1). The validation cohort consisted of 188 various subtypes of MDS patients diagnosed and treated in Shanghai Ruijin Hospital and Shanghai No.6 People’s Hospital. All patients provided written informed consent. Bone marrow and paired buccal samples were obtained after informed consent. DNA sample preparation. Mononuclear cells (MNC) were separated by density gradient centrifugation using Ficoll in 8 RAEB patients and 188 MDS patients from validation cohort. Subsequently, CD34+ cells were isolated by magnetic cell separation (Miltenyi Biotech, Bergisch Gladbach, Germany) to reach a purity of 89-97.7% (average: 93.1%) in 8 RAEB patients. Flow through CD34- cells were also collected for analysis. Skin biopsy was obtained for analysis of normal genome and extracted by DNeasy Blood & Tissue Kit (Qiagen). Genomic DNA of CD34+ cells were isolated by QuickGene DNA whole blood kit L (FUJIFILM, Life Science). Genomic DNA of MNC from validation set was extracted by Wizard® Genomic DNA Purification Kit (Promega). DNA library preparation. Genomic DNA was sheared by sonication 1 and adaptors were ligated to the resulting fragments.
    [Show full text]
  • 1 Genome-Wide Comparisons of Variation in Linkage Disequilibrium
    Downloaded from genome.cshlp.org on September 30, 2021 - Published by Cold Spring Harbor Laboratory Press Genome-wide comparisons of variation in linkage disequilibrium Yik Y. Teo1,*, Andrew E. Fry1, Kanishka Bhattacharya1, Kerrin S. Small1, Dominic P. Kwiatkowski1,2, Taane G. Clark1,2 1 Wellcome Trust Centre for Human Genetics, University of Oxford, United Kingdom 2 Wellcome Trust Sanger Institute, Hinxton, United Kingdom Running title: Genome-wide comparisons of LD Keywords: linkage disequilibrium, imputation, positive selection, meta-analysis, genome-wide association study * Corresponding author: Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7BN, United Kingdom. Email: [email protected], phone: +44 1865 287712, fax: +44 1865 287 501. ABSTRACT Current genome-wide surveys of common diseases and complex traits fundamentally aim to detect indirect associations where the SNPs carrying the association signals are not biologically active but are in linkage disequilibrium (LD) with some unknown functional polymorphisms. Reproducing any novel discoveries from these genome-wide scans in independent studies is now a prerequisite for the putative findings to be accepted. Significant differences in patterns of LD between populations can affect the portability of phenotypic associations when the replication effort or meta-analyses are attempted in populations that are distinct from the original population which the genome-wide study is performed in. Here we introduce a novel method for genome-wide analyses of LD variations between populations that allow the identification of candidate regions with different patterns of LD. The evidence of LD variation provided by the introduced method correlated with the degree of differences in the frequencies of the most common haplotype across the populations.
    [Show full text]
  • DNMT Inhibitors Increase Methylation at Subset of Cpgs in Colon
    bioRxiv preprint doi: https://doi.org/10.1101/395467; this version posted August 25, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Title: DNMT inhibitors increase methylation at subset of CpGs in colon, bladder, lymphoma, 2 breast, and ovarian, cancer genome 3 Running title: Decitabine/azacytidine increases DNA methylation 4 Anil K Giri1, Tero Aittokallio1,2 5 1Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland. 6 2Department of Mathematics and Statistics, University of Turku, Turku, Finland. 7 Correspondence to 8 Dr. Anil K Giri 9 Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland. 10 Email: [email protected] 11 Financial disclosure: This work was funded by the Academy of Finland (grants 269862, 292611, 12 310507 and 313267), Cancer Society of Finland, and the Sigrid Juselius Foundation. 13 Ethical disclosure: This study is an independent analysis of existing data available in the public 14 domain and does not involve any animal or human samples that have been collected by the authors 15 themselves. 16 Author contribution: AKG conceptualized, analyzed the data and wrote the manuscript. TA 17 critically revised and edited the manuscript. The authors report no conflict of interest. 18 19 Word count: 20 Figure number: 5 21 Table number: 1 22 23 Abstract 24 Background: DNA methyltransferase inhibitors (DNMTi) decitabine and azacytidine are approved 25 therapies for acute myeloid leukemia and myelodysplastic syndrome.
    [Show full text]
  • Differentially Methylated Genes
    10/30/2013 Disclosures Key Rheumatoid Arthritis-Associated Pathogenic Pathways Revealed by Integrative Analysis of RA Omics Datasets Consultant: IGNYTA Funding: Rheumatology Research Foundation By John W. Whitaker, Wei Wang and Gary S. Firestein DNA methylation and gene regulation The RA methylation signature in FLS DNA methylation – DNMT1 (maintaining methylation) OA – DNMT3a, 3b (de novo methylation) RA % of CpG methylation: 0% 100% Nakano et al. 2013 ARD AA06 AANAT AARS ABCA6 ABCC12 ABCG1 ABHD8 ABL2 ABR ABRA ACACA ACAN ACAP3 ACCSL ACN9 ACOT7 ACOX2 ACP5 ACP6 ACPP ACSL1 ACSL3 ACSM5 ACVRL1 ADAM10 ADAM32 ADAM33 ADAMTS12 ADAMTS15 ADAMTS19 ADAMTS4 ADAT3 ADCK4 ADCK5 ADCY2 ADCY3 ADCY6 ADORA1 ADPGK ADPRHL1 ADTRP AFAP1 AFAP1L2 AFF3 AFG3L1P AGAP11 AGER AGTR1 AGXT AIF1L AIM2 AIRE AJUBA AK4 AKAP12 AKAP2 AKR1C2 AKR1E2 AKT2 ALAS1 ALDH1L1-AS1 ALDH3A1 ALDH3B1 ALDH8A1 ALDOB ALDOC ALOX12 ALPK3 ALS2CL ALX4 AMBRA1 AMPD2 AMPD3 ANGPT1 ANGPT2 ANGPTL5 ANGPTL6 ANK1 ANKMY2 ANKRD29 ANKRD37 ANKRD53 ANO3 ANO6 ANO7 ANP32C ANXA6 ANXA8L2 AP1G1 AP2A2 AP2M1 AP5B1 APBA2 APC APCDD1 APOBEC3B APOBEC3G APOC1 APOH APOL6 APOLD1 APOM AQP1 AQP10 AQP6 AQP9 ARAP1 ARHGAP24 ARHGAP42 ARHGEF19 ARHGEF25 ARHGEF3 ARHGEF37 ARHGEF7 ARL4C ARL6IP 5 ARL8B ARMC3 ARNTL2 ARPP21 ARRB1 ARSI ASAH2B ASB10 ASB2 ASCL2 ASIC4 ASPH ATF3 ATF7 ATL1 ATL3 ATP10A ATP1A1 ATP1A4 ATP2C1 ATP5A1 ATP5EP2 ATP5L2 ATP6V0CP3 ATP6V1C1 ATP6V1E2 ATXN7L1 ATXN7L2 AVPI1 AXIN2 B3GNT7 B3GNT8 B3GNTL1 BACH1 BAG3 Differential methylated genes in RA FLS BAIAP2L2 BANP BATF BATF2 BBS2 BCAS4 BCAT1 BCL7C BDKRB2 BEGAIN BEST1 BEST3
    [Show full text]
  • WO 2019/068007 Al Figure 2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2019/068007 Al 04 April 2019 (04.04.2019) W 1P O PCT (51) International Patent Classification: (72) Inventors; and C12N 15/10 (2006.01) C07K 16/28 (2006.01) (71) Applicants: GROSS, Gideon [EVIL]; IE-1-5 Address C12N 5/10 (2006.0 1) C12Q 1/6809 (20 18.0 1) M.P. Korazim, 1292200 Moshav Almagor (IL). GIBSON, C07K 14/705 (2006.01) A61P 35/00 (2006.01) Will [US/US]; c/o ImmPACT-Bio Ltd., 2 Ilian Ramon St., C07K 14/725 (2006.01) P.O. Box 4044, 7403635 Ness Ziona (TL). DAHARY, Dvir [EilL]; c/o ImmPACT-Bio Ltd., 2 Ilian Ramon St., P.O. (21) International Application Number: Box 4044, 7403635 Ness Ziona (IL). BEIMAN, Merav PCT/US2018/053583 [EilL]; c/o ImmPACT-Bio Ltd., 2 Ilian Ramon St., P.O. (22) International Filing Date: Box 4044, 7403635 Ness Ziona (E.). 28 September 2018 (28.09.2018) (74) Agent: MACDOUGALL, Christina, A. et al; Morgan, (25) Filing Language: English Lewis & Bockius LLP, One Market, Spear Tower, SanFran- cisco, CA 94105 (US). (26) Publication Language: English (81) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of national protection available): AE, AG, AL, AM, 62/564,454 28 September 2017 (28.09.2017) US AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 62/649,429 28 March 2018 (28.03.2018) US CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (71) Applicant: IMMP ACT-BIO LTD.
    [Show full text]
  • Identification of Genetic Factors Underpinning Phenotypic Heterogeneity in Huntington’S Disease and Other Neurodegenerative Disorders
    Identification of genetic factors underpinning phenotypic heterogeneity in Huntington’s disease and other neurodegenerative disorders. By Dr Davina J Hensman Moss A thesis submitted to University College London for the degree of Doctor of Philosophy Department of Neurodegenerative Disease Institute of Neurology University College London (UCL) 2020 1 I, Davina Hensman Moss confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. Collaborative work is also indicated in this thesis. Signature: Date: 2 Abstract Neurodegenerative diseases including Huntington’s disease (HD), the spinocerebellar ataxias and C9orf72 associated Amyotrophic Lateral Sclerosis / Frontotemporal dementia (ALS/FTD) do not present and progress in the same way in all patients. Instead there is phenotypic variability in age at onset, progression and symptoms. Understanding this variability is not only clinically valuable, but identification of the genetic factors underpinning this variability has the potential to highlight genes and pathways which may be amenable to therapeutic manipulation, hence help find drugs for these devastating and currently incurable diseases. Identification of genetic modifiers of neurodegenerative diseases is the overarching aim of this thesis. To identify genetic variants which modify disease progression it is first necessary to have a detailed characterization of the disease and its trajectory over time. In this thesis clinical data from the TRACK-HD studies, for which I collected data as a clinical fellow, was used to study disease progression over time in HD, and give subjects a progression score for subsequent analysis. In this thesis I show blood transcriptomic signatures of HD status and stage which parallel HD brain and overlap with Alzheimer’s disease brain.
    [Show full text]
  • Sean Raspet – Molecules
    1. Commercial name: Fructaplex© IUPAC Name: 2-(3,3-dimethylcyclohexyl)-2,5,5-trimethyl-1,3-dioxane SMILES: CC1(C)CCCC(C1)C2(C)OCC(C)(C)CO2 Molecular weight: 240.39 g/mol Volume (cubic Angstroems): 258.88 Atoms number (non-hydrogen): 17 miLogP: 4.43 Structure: Biological Properties: Predicted Druglikenessi: GPCR ligand -0.23 Ion channel modulator -0.03 Kinase inhibitor -0.6 Nuclear receptor ligand 0.15 Protease inhibitor -0.28 Enzyme inhibitor 0.15 Commercial name: Fructaplex© IUPAC Name: 2-(3,3-dimethylcyclohexyl)-2,5,5-trimethyl-1,3-dioxane SMILES: CC1(C)CCCC(C1)C2(C)OCC(C)(C)CO2 Predicted Olfactory Receptor Activityii: OR2L13 83.715% OR1G1 82.761% OR10J5 80.569% OR2W1 78.180% OR7A2 77.696% 2. Commercial name: Sylvoxime© IUPAC Name: N-[4-(1-ethoxyethenyl)-3,3,5,5tetramethylcyclohexylidene]hydroxylamine SMILES: CCOC(=C)C1C(C)(C)CC(CC1(C)C)=NO Molecular weight: 239.36 Volume (cubic Angstroems): 252.83 Atoms number (non-hydrogen): 17 miLogP: 4.33 Structure: Biological Properties: Predicted Druglikeness: GPCR ligand -0.6 Ion channel modulator -0.41 Kinase inhibitor -0.93 Nuclear receptor ligand -0.17 Protease inhibitor -0.39 Enzyme inhibitor 0.01 Commercial name: Sylvoxime© IUPAC Name: N-[4-(1-ethoxyethenyl)-3,3,5,5tetramethylcyclohexylidene]hydroxylamine SMILES: CCOC(=C)C1C(C)(C)CC(CC1(C)C)=NO Predicted Olfactory Receptor Activity: OR52D1 71.900% OR1G1 70.394% 0R52I2 70.392% OR52I1 70.390% OR2Y1 70.378% 3. Commercial name: Hyperflor© IUPAC Name: 2-benzyl-1,3-dioxan-5-one SMILES: O=C1COC(CC2=CC=CC=C2)OC1 Molecular weight: 192.21 g/mol Volume
    [Show full text]
  • Genome-Wide Analysis Distinguishes Hyperglycemia Regulated Epigenetic Signatures of Primary Vascular Cells
    Downloaded from genome.cshlp.org on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press Research Genome-wide analysis distinguishes hyperglycemia regulated epigenetic signatures of primary vascular cells Luciano Pirola,1,8 Aneta Balcerczyk,1,8 Richard W. Tothill,2 Izhak Haviv,3 Antony Kaspi,1 Sebastian Lunke,1 Mark Ziemann,1,2 Tom Karagiannis,1 Stephen Tonna,1 Adam Kowalczyk,4 Bryan Beresford-Smith,4 Geoff Macintyre,4 Ma Kelong,5 Zhang Hongyu,5 Jingde Zhu,5 and Assam El-Osta1,2,6,7,9 1Epigenetics in Human Health and Disease Laboratory, Baker IDI Heart and Diabetes Institute, The Alfred Medical Research and Education Precinct, Melbourne, Victoria 3004, Australia; 2Epigenomic Profiling Facility, Baker IDI Heart and Diabetes Institute, The Alfred Medical Research and Education Precinct, Melbourne, Victoria 3004, Australia; 3Bioinformatics & Systems Integration, Baker IDI Heart and Diabetes Institute, The Alfred Medical Research and Education Precinct, Melbourne, Victoria 3004, Australia; 4NICTA Victoria Research Laboratory, Department of Electrical and Electronic Engineering, The University of Melbourne, Victoria 3010, Australia; 5Shanghai Cancer Institute, Jiaotong University, Shanghai 200032, China; 6Department of Pathology, The University of Melbourne, Victoria 3010, Australia; 7Faculty of Medicine, Monash University, Victoria 3800, Australia Emerging evidence suggests that poor glycemic control mediates post-translational modifications to the H3 histone tail. We are only beginning to understand the dynamic role of some of the diverse epigenetic changes mediated by hyper- glycemia at single loci, yet elevated glucose levels are thought to regulate genome-wide changes, and this still remains poorly understood. In this article we describe genome-wide histone H3K9/K14 hyperacetylation and DNA methylation maps conferred by hyperglycemia in primary human vascular cells.
    [Show full text]